Fresh insights into the effect of combination myopia treatment with the MiYOSMART defocus spectacle lens and low dose atropine were presented at the recent International Myopia Conference (IMC) in Rotterdam, The Netherlands.
Ophthalmic lens manufacturer HOYA Vision Care, a diamond sponsor of IMC held 4-7 September, hosted a myopia symposium where experts shared their latest findings of the clinical application of the MiYOSMART spectacle lens in myopia management.
Under the theme – ‘The latest insights to advance myopia management’ – renowned key opinion leaders shared new European data and discussed topics including emmetropic eye growth, combination treatment and relative peripheral refraction (RPR).
Dr Andrea Lembo, of the University Hospital San Giuseppe Multimedica in Milan, Italy, shared the results of a clinical application of MiYOSMART in combination with 0.01% atropine drops in European myopic children and adolescents.1
The results demonstrated that over one-year, axial elongation and myopia progression were reduced with maximum effect using the combination treatment,1 HOYA stated.
“We are very pleased to be able to share the latest evidence-based approach to myopia management at IMC 2022,” said Ms May Zhang, HOYA Vision Care’s global head of professional affairs.
“HOYA Vision Care continues to be a leader in addressing myopia in children and championing new practices like the successful combination treatment of the MiYOSMART spectacle lens and atropine drops as well as continued support of clinical studies in multiple countries to help eyecare professionals make informed decisions.”
Meanwhile, Professor Hakan Kaymak from the Internationale Innovative Ophthalmochirurgie in Duesseldorf, Germany, presented the findings of his study on axial length growth under MiYOSMART treatment.
“The data of German children wearing the lens reconfirmed previous clinical study results” HOYA stated.1 “Further findings showed that children adapt very well to MiYOSMART spectacle lenses with no safety concerns even in combination with low-dose atropine.”1
In addition, Professor Carly Lam, of The Hong Kong Polytechnic University, shared how myopia control effect may be influenced by baseline relative peripheral refraction in children wearing the MiYOSMART spectacle lens with D.I.M.S. Technology.1
The results showed that myopia control effect was stronger in children with baseline hyperopic RPR than in children with baseline myopic RPR.1
Since its launch in 2018, MiYOSMART is available in 28 markets, and became available in Australia and New Zealand in October 2020, with more than two million spectacle lenses purchased by parents globally.2
More information about the MiYOSMART lens can be found here.
More reading
Managing myopia with spectacle lenses – CPD
Is two better than one? Combining treatments for myopia control
A myopia first: Hoya lens shows long-term efficacy
References
- Kaymak H, Lembo A, Lam CSY. HOYA Vision Care Myopia Symposium ” New Insights to Advance Myopia Management”: Axial length growth under therapy with MiYOSMART spectacle lenses; A comparison of myopia control in European children with Defocus Incorporated Multiple Segments (DIMS) spectacles, atropine, and combined DIMS/atropine; Myopia control effect is influenced by baseline relative peripheral refraction in children wearing Defocus Incorporated Multiple Segments (DIMS) spectacle lenses. International Myopia Conference (IMC) 2022, September 4, Rotterdam, The Netherlands.
- Based on number of MiYOSMART lenses sold per Hoya sales data on file as of June 2022.
